Doctolib's primary-care platform bet: 12 loss-making years, then profit and UK expansion

Doctolib is a health-tech SaaS platform: practices use it to manage appointments, patient documents, notes and invoices, with telehealth and secure messaging add-ons, while patients get a free booking app; it operates in France, Germany, Italy, the Netherlands and, since May 2026, the UK.

That doctors would pay for booking software and patients adopt the free app, making Doctolib the default layer under European primary care once it reached scale.

Founded in France in 2013, Doctolib began as an online booking platform connecting doctors and patients, sold to independent practices as software that removed phone queues and paper diaries. TechCrunch describes the product as SaaS for doctors and medical workers to tackle administrative tasks, with patients on the free side of the network.

Covid-19 turned Doctolib into essential national infrastructure: the French government promoted it for vaccination and test bookings and millions of people created accounts. By March 2022 it had 60 million users across France, Germany and Italy and 300,000 healthcare workers, and raised €500 million ($549 million) in equity and debt at a €5.8 billion ($6.4 billion) valuation - at the time the highest of any French startup - led by Eurazeo with Bpifrance and General Atlantic, planning to grow from 2,500 to 6,000 staff. It kept losing money while expanding products (Doctolib Médecin, Doctolib Team, telehealth, encryption via Tanker) and markets; Clubic puts its 2024 EBITDA at roughly minus €54 million.

In late October 2025 co-founder Stanislas Niox-Chateau told BFMTV that Doctolib had become profitable for the first time since its 2013 founding, saying profitability lets the company be master of its own destiny. On 2026-05-06 it announced the acquisition of Medicus, maker of practice-management software for NHS general practitioners, with plans to invest over £100 million, hire 150 people and open a UK R&D centre - its fifth European market. Still private and expanding.

It bet on the supply side first: selling booking SaaS to independent doctors, whose adoption then pulls in patients, instead of building a consumer app and hoping doctors would join.

Covid turned the bet into a national habit: government-promoted vaccination and test booking brought millions of users and made Doctolib the default way to see a doctor in France.

It carried years of losses deliberately, reinvesting into product breadth (documents, invoicing, telehealth, messaging, encryption) and acquisitions across Germany, Italy and the Netherlands.

The resulting network - 400,000 health professionals and 80 million users - is what finally made subscriptions profitable in 2025 and funds new entries such as the UK.

Losses are only worth carrying while they buy two-sided network scale: Doctolib's 12 years of red ink built the doctor-patient default that finally made its subscriptions profitable.

As of 2026-05-06 Doctolib is running and scaling: profitable for the first time since its 2013 founding, with roughly 50 million users in France, 80 million across Europe, 400,000 health professionals and about 3,000 staff. Its May 2026 acquisition of Medicus opens the UK - its fifth market after France, Germany, Italy and the Netherlands - backed by over £100 million of planned investment, and it is adding AI products for patients and caregivers. The company remains private; its last primary round, in March 2022, valued it at €5.8 billion, and no IPO or shutdown has been announced.